Insight

Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC

Photo from clinicaloptions.com

Sep 12, 2024, 09:48

Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC

Erman Akkus shared a post on X about a recent paper by Myung-Ju Ahn et al. published in JCO.

“Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study”

Authors: Myung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares, Aaron Lisberg, Jacob Sands et al.

“Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC.

TROPION-Lung01

Improved PFS in nonsquamous histology
5.5 vs3.6 mo, HR: 0.63 (0.51-0.79)
Not OS
Not PFS or OS in squamous histology.”

Source: Erman Akkus/X

Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.

Aaron Lisberg cancer Dato-DXd datopotamab deruxtecan docetaxel Erman Akkus Jacob Sands JCO Kentaro Tanaka Luis Paz-Ares metastatic non-small cell lung cancer mNSCLC Myung-Ju Ahn NSCLC OncoDaily Oncology TROPION-Lung01

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Isabel Mestres: In a world where the fight against cancer knows no borders, collaboration is not optional - it’s essential

Bernard Fox received SITC lifetime achievement award

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Special Coverage